Skip to content
value.today
Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc.

🇺🇸 New York, New York, USATechnologyFounded 2014
Total raised
$106 M
3 rounds on record
Latest round
$26 M
Jan 2017
First round on record
Oct 2014
Today
Went public
See the company page

Ovid Therapeutics Inc. is listed today as Ovid Therapeutics Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Ovid Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2017$26 MNo. 3$10 to $50 million

Ovid Therapeutics Inc.: Raise no. 3, Jan 2017

Investors in this round

1 investor had bought by the notice of Jan 20, 2017: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Ovid Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$26 M of $26 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Amit E. Rakhit · Executive Officer
  • Jeremy M. Levin · Executive Officer, Director
  • Matthew J. During · Executive Officer, Director
  • Yaron M. Werber · Executive Officer
  • Bart M. Friedman · Director
  • Douglas E. Williams · Director
  • Karen E. Bernstein · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Yaron Werber, Chief Business & Financial Officer. Newest notice filed Jan 20, 2017. Read the notice at the SEC.

equitySEC
Aug 2015$75 MNo. 2$50 to $250 million

Ovid Therapeutics Inc.: Raise no. 2, Aug 2015

Investors in this round

50 investors had bought by the notice of Aug 18, 2015: 50 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Ovid Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$75 M of $75 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$3,995,998
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeremy M. Levin · Executive Officer, Director
  • Matthew J. During · Executive Officer, Director
  • Yaron M. Werber · Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cowen and Company, LLC (CRD 7616) · New York, New YorkSold in CA, IL, MA, MD, NJ, NY

Signed by Jeremy M. Levin, Chief Executive Officer. Newest notice filed Aug 18, 2015. Read the notice at the SEC.

equitySEC
Oct 2014$5 MNo. 1$2 to $10 million

Ovid Therapeutics Inc.: Raise no. 1, Oct 2014

Investors in this round

5 investors had bought by the notice of Mar 18, 2015: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Ovid Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeremy M. Levin · Executive Officer, Director
  • Matthew J. During · Executive Officer, Director
  • Mark M. Feldberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Matthew J. During, President. Newest notice filed Mar 18, 2015. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Ovid Therapeutics Inc., its revenue in fiscal 2025 came from these business segments: Reportable $7.25 million (100%).

    Annual report (SEC XBRL) · Dec 2025

  • Ovid Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2017).

    SEC Form D · Jan 2017

  • The industry group it chose in its notices: Other Technology.

    SEC Form D · Jan 2017

Products and services#

No products or services of Ovid Therapeutics Inc. are on record.

Investors#

4 named in official filings. Open an investor to see everything it has backed.

Investors in Ovid Therapeutics Inc.
InvestorKindAmountRoundRoleSource
Jeremy M. LevinPersonnot statednot statedHeld Series A preferred stock, 10% owner, director (Form 3, 2017)SEC Form 3
Matthew DuringPersonnot statednot statedHeld Series A preferred stock, 10% owner, director (Form 3, 2017)SEC Form 3
Millennium Pharmaceuticals IncCompanynot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Takeda Pharmaceutical Co LTDCompanynot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2019)SEC Form 3

Largest shareholders today

Institutions holding Ovid Therapeutics Inc. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Ovid Therapeutics Inc.
NameRoleNamed in
Amit E. RakhitExecutive officerJan 2017
Jeremy M. LevinExecutive officerJan 2017
Matthew J. DuringExecutive officerJan 2017
Yaron M. WerberExecutive officerJan 2017
Bart M. FriedmanDirectorJan 2017
Douglas E. WilliamsDirectorJan 2017
Jeremy M. LevinDirectorJan 2017
Karen E. BernsteinDirectorJan 2017
Matthew J. DuringDirectorJan 2017
Mark M. FeldbergDirectorMar 2015

Went public since 2017. Its SEC number is that of a company listed on a stock exchange.